By Al Long
Director of Chemistry, Lead Optimization, Merial
May 1, 2017
Merial, a wholly-owned subsidiary of Boehringer-Ingelheim, develops pharmaceutical drugs, biological vaccines, and wellness products for a range of animal health issues. Merial has pioneered a business model of outsourcing and contracting for services at different points in the value chain, providing access to and benefiting from complementary competencies outside the firm.
Merial Pharma Discovery & Research has implemented an advanced research informatics platform for sharing data and communicating with our worldwide network of research partners. Our chemistry partners in the USA and China upload data associated with the synthetic processes and we at Merial, as the sponsor, can rapidly review and provide feedback. Our CRO partners in the USA run biological screens on molecules in the Discovery program and the data is securely shared with Merial. By orchestrating the research processes, Merial owns the high-end of the drug discovery value chain. This has resulted in high productivity and tangible business outcomes; two drug candidates have recently reached the clinical testing phase.